Healthcare research company Tevogen Bio reported on Monday the receipt of the necessary funding to support all clinical trials of its investigational, potentially curative COVID-19 treatment from HMP Partners of New Jersey, a medical investment firm.
The company said its Investigational New Drug (IND) application for its proprietary antigen-specific T cell therapy is under review by the US Food and Drug Administration (FDA).
According to the company, a patient's own T cells reportedly activates and responds to the infection, which is the mechanism that the body employs to rid itself of SARS-CoV-2. Its proprietary solution enables a single donation from a donor to generate more than a thousand doses of COVID-19 specific cytotoxic T cells.
Yale's Dr Ryan Saadi is leading the efforts and is among those who are financing the trials.
Under the guidance of the lead investigator Dr Neal Flomenberg, chair of the Department of Medical Oncology at Thomas Jefferson University, Tevogen will study its investigational treatment, TVGN-489, allogeneic T cells that have been programmed and grown in the laboratory, for its safety and capability to recognize and destroy COVID-19 infected cells in its upcoming trials.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study